California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Companies to develop bispecific antibodies.
Doubts over Juno CAR-T therapy after two more trial deaths.
FDA lifts partial clinical hold.
Initiative aims to find new immunotherapies.
Backed by Amgen, Kite outlines bold plan for developing CAR-T and TCR cells.
Cancer immunotherapy approved in second line.